HSBC/CALL/MODERNA/320/0.1/15.01.25 | Market Closed - Boerse Frankfurt Warrants 03:35:50 2024-07-16 pm EDT | ||
| 0.08 EUR | +8.11% |
|
| Current month | +92.86% | ||
| 1 month | -31.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.081 | +9.46% |
| 24-07-15 | 0.074 | +4.23% |
| 24-07-12 | 0.071 | -12.35% |
| 24-07-11 | 0.081 | +19.12% |
| 24-07-10 | 0.068 | +15.25% |
Real-time Boerse Frankfurt Warrants
Last update July 16, 2024 at 03:35 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG807Q |
| ISIN | DE000HG807Q0 |
| Date issued | 2023-02-02 |
| Strike | 320 $ |
| Maturity | 2025-01-15 (183 Days) |
| Parity | 10 : 1 |
| Emission price | 2.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.11 € |
|---|---|
| Lowest since issue | 0.007 € |
| Spread | 0.015 € |
| Spread % | 16.13% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
125.1
USD
Average target price
145.9
USD
Spread / Average Target
+16.59%
- Stock Market
- Warrants
- Warrant
